StockMarketWire.com - IXICO, the digital technologies company serving neuroscience, has signed a new contract with a North American based biopharmaceutical company worth £1.2m over a three-year term.

IXICO said it would provide its technology enabled imaging services in a phase II clinical trial of a novel therapeutic to treat people with Huntington's disease.

IXICO said that as part of the study, it would use its TrialTracker digital platform and scientific services to standardise the acquisition and collection of both MRI and PET scans acquired at specialist imaging centres across North America.

It said this data would be analysed using IXICO's proprietary image analysis workflows and algorithms to evaluate patient eligibility, monitor patient safety and quantify drug effects.


At 8:21am: [LON:IXI] IXICO plc share price was +1p at 34p



Story provided by StockMarketWire.com